Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company focused on minimally invasive surgical technologies for sacropelvic disorders, including sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, spinopelvic and sacropelvic fixation, and pelvic trauma. This news page aggregates company press releases and market updates related to SIBN stock and SI-BONE’s sacropelvic platform.
Investors following SI-BONE news can expect regular updates on quarterly and annual financial results, preliminary revenue announcements, and changes to financial guidance. Recent communications have highlighted double-digit worldwide and U.S. revenue growth, gross margin performance, adjusted EBITDA trends, and cash and cash equivalents. The company also reports operational metrics such as the number of active U.S. physicians using its technologies and revenue per sales territory.
Beyond earnings, SI-BONE’s news flow includes information on reimbursement developments, such as New Technology Add-on Payments and other payment designations for procedures involving products like iFuse TORQ TNT and iFuse Bedrock Granite. The company also issues 8-K-linked press releases covering leadership and board changes, including retirements, consulting agreements, and commercial leadership transitions.
Another recurring theme in SI-BONE news is participation in healthcare and medtech investor conferences hosted by firms such as Piper Sandler, Morgan Stanley, Canaccord Genuity, Truist Securities, and Goldman Sachs. These events often feature fireside chats or presentations where management discusses sacropelvic technologies, clinical evidence, and financial performance, with webcasts made available through the investors section of SI-BONE’s website.
For anyone tracking SIBN, this page offers a centralized view of SI-BONE’s earnings releases, preliminary updates, conference appearances, and other company announcements related to its sacropelvic surgical technology platform.
SI-BONE, Inc. (Nasdaq:SIBN) reported a 26% increase in worldwide revenue to $20.4 million for Q3 2020, compared to Q3 2019. U.S. revenue rose 27% to $18.9 million, driven by increased domestic case volumes. The company surpassed 50,000 iFuse procedures with over 2,200 surgeons. Despite a gross margin decline to 87% from 90%, operating loss decreased to $8.7 million. Cash reserves stand at $132 million. The company anticipates full-year revenue guidance of $73-$74 million, reflecting 8%-10% growth, while acknowledging potential COVID-19 risks.
SI-BONE, Inc. (Nasdaq: SIBN) has scheduled its third quarter 2020 financial results announcement for November 2, 2020, after market close. Management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss results. The iFuse Implant System, the company’s flagship product for sacroiliac joint fusion, has shown significant clinical benefits, with over 80 peer-reviewed publications reinforcing its effectiveness. The device is covered by multiple insurance payors, highlighting its market acceptance and clinical validation.
SI-BONE, Inc. (SIBN) announced the pricing of a public offering of 3,190,053 shares of its common stock at $22.00 per share, aiming to raise approximately $66 million. Of the shares, 3,000,000 are from SI-BONE and 190,053 from a selling stockholder. The offering is set to close on October 19, 2020, with underwriters also granted a 30-day option for an additional 478,507 shares. Morgan Stanley and BofA Securities are the main managers of this offering. The funds will support the company's surgical treatment technologies for sacropelvic anatomy.
SI-BONE, Inc. (SIBN) announced an underwritten public offering of 3,190,053 shares of its common stock, with an additional option for underwriters to purchase 478,507 shares. SI-BONE will offer 3,000,000 shares while a selling stockholder will offer 190,053 shares. The offering hinges on market conditions, and completion timelines remain uncertain. Morgan Stanley and BofA Securities are the lead managers, complemented by Cantor Fitzgerald, JMP Securities, and Needham & Company as co-managers. The offering follows a shelf registration effective since January 2020.
SI-BONE, Inc. (Nasdaq:SIBN) announced preliminary unaudited revenue for Q3 and the first nine months of 2020. Q3 revenue is anticipated between $20.1-$20.4 million, marking a 24%-26% increase year-over-year. U.S. revenue is estimated at $18.7-$18.9 million with a 26%-27% growth. For the nine months, revenue is expected between $51.0-$51.3 million, an 8%-10% increase from 2019. Despite this growth, SI-BONE expresses caution due to the ongoing impacts of COVID-19. Third-quarter results will be disclosed on November 2, 2020.
SI-BONE, a medical device company, announced a virtual surgeon panel led by CEO Jeffrey Dunn on October 8, 2020, from 10am to 11am ET. The panel will feature renowned experts discussing the treatment of sacroiliac joint dysfunction and the role of telehealth in surgery.
Panelists include Dr. Peter Whang from Yale, Dr. Bharat Desai from Panorama Orthopedics, Dr. William Tobler from Mayfield Clinic, and Dr. Robert Eastlack from Scripps Health. Interested attendees can register through SI-BONE’s investor relations website.
SI-BONE, a leader in medical devices for musculoskeletal disorders, announced its participation in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference and 2020 Cantor Global Healthcare Conference. Management will present at a Fireside Chat on September 15, 2020, at 5:00 p.m. ET and September 16, 2020, at 12:20 p.m. ET. Interested parties can access the live and archived webcasts on the company's website. The company is known for its iFuse Implant System, designed for minimally invasive SI joint fusion, supported by extensive clinical studies.
SI-BONE, Inc. (Nasdaq:SIBN) reported Q2 2020 financial results, with revenue of $14.0 million, a 14% decrease year-over-year. U.S. revenue totaled $13.2 million, down 12%. International revenue fell by 36% to $0.8 million, largely due to COVID-19's impact on surgical volumes. The company completed a $40 million debt refinancing and received positive coverage from Aetna, covering over 22 million members. The gross margin decreased to 85% from 90%, and the net loss widened to $12.5 million or $0.44 per diluted share. Guidance for 2020 remains withdrawn amid ongoing uncertainty.
SI-BONE, a medical device company focused on sacropelvic disorders, announced its participation in the 40th Annual Canaccord Genuity Growth Conference. The company will conduct a live Fireside Chat on August 12, 2020, at 1:00 p.m. ET. Interested individuals can access the webcast via the company's website. SI-BONE's iFuse Implant System, designed for minimally invasive sacroiliac joint fusion, is supported by multiple clinical studies demonstrating its effectiveness in treating chronic low back pain. The device has been commercially available since 2009 and is covered by various insurance payors.
SI-BONE, Inc. (Nasdaq: SIBN) will announce its Q2 2020 financial results post-market on August 3, 2020. The management team will host a conference call at 1:30 PM PT, accessible via the company’s website. SI-BONE specializes in minimally invasive surgical solutions for sacropelvic disorders, notably through its iFuse Implant System, which addresses chronic low back pain. Supported by numerous clinical studies, the iFuse Implant is the only SI joint fusion device with established insurance coverage for the procedure. Detailed company and product information can be found on their website.